CSL Limited (OTCMKTS:CSLLY – Get Rating) – Stock analysts at Jefferies Financial Group decreased their FY2022 EPS estimates for CSL in a research report issued to clients and investors on Wednesday, August 3rd. Jefferies Financial Group analyst D. Stanton now expects that the company will earn $2.43 per share for the year, down from their previous forecast of $2.55. The consensus estimate for CSL’s current full-year earnings is $2.49 per share. Jefferies Financial Group also issued estimates for CSL’s FY2023 earnings at $2.64 EPS and FY2024 earnings at $3.22 EPS.
CSL Trading Down 0.1 %
Shares of CSLLY stock opened at $102.40 on Friday. The firm has a fifty day moving average of $96.85 and a 200-day moving average of $96.27. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.94 and a quick ratio of 3.43. CSL has a 12-month low of $85.07 and a 12-month high of $117.24.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
- Get a free copy of the StockNews.com research report on CSL (CSLLY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.